top of page

India | Drug Approvals | Pharma News | 2024 | iPharmaCenter

January 03, 2024

AstraZeneca India Unveils Trastuzumab Deruxtecan for HER2-Positive Metastatic Cases

AstraZeneca India has officially launched trastuzumab deruxtecan, a specialized intervention devised for the management of adult patients grappling with unresectable or metastatic HER2 positive breast cancer, initiating from January 2024. This inventive treatment, co-created with Daiichi Sankyo, incorporates a HER2-targeted antibody-drug conjugate (ADC).


Breast cancer stands as a noteworthy global health issue, with over 2 million instances documented in 2020, establishing it as the most identified cancer according to the World Health Organization (WHO). In India, there has been a significant 40% uptick in the frequency of breast cancer over the past 25 years. Trastuzumab deruxtecan marks a substantial leap in addressing the vital medical requirements of patients contending with HER2-positive metastatic breast cancer.


The initiation of trastuzumab deruxtecan is supported by affirmative outcomes from the DESTINY-Breast03 trial, a worldwide Phase III investigation. The primary findings, disclosed in The New England Journal of Medicine, suggest an impressive 72% reduction in the hazard of ailment progression or demise compared to trastuzumab emtansine (T-DM1). Updated outcomes, published in The Lancet, indicate a 36% decrease in the threat of demise versus T-DM1. Significantly, 77.4% of patients treated with trastuzumab deruxtecan survived at the two-year mark, spotlighting the enduring impact of this pioneering therapy across diverse patient subdivisions. The median progression-free survival, as ascertained by an impartial central review, was a noteworthy 28.8 months with trastuzumab deruxtecan in contrast to 6.8 months with T-DM1, reinforcing its standing as a transformative intervention in breast cancer care.


AstraZeneca India stated that this therapy brings reinvigorated optimism and enhanced consequences for patients grappling with HER2-positive metastatic breast cancer. The Drug Controller General of India (DCGI) granted authorization for the import and promotion of trastuzumab deruxtecan to AstraZeneca India in May 2023.

Recent Posts

See All

Comments


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page